Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Kozauer and Mr. Miller entering into employment with LB Pharmaceuticals.
- Basel Medical Group Ltd (BMGL) Closes Registered Direct OfferingBasel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today closed its registered direct offering of 6,000,000 units, raising gross proceeds of US$7.98 million and estimated net proceeds of approximately US$7.28 million. The Company intends to use all of the net proceeds from this offering for general working capital purposes, mergers and acquisitions and other general corporate purposes.
- Evolent Health, Inc.Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, before market open,...
- CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyCytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
- Secure Healthcare Information Management Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Patient Data Is ExposedEdelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at Secure Healthcare Info
- Universal Health Services, Inc. Announces Date and Time Change for Third Quarter 2026 Earnings Release and Conference CallCompanies: Universal Health ServicesUniversal Health Services, Inc. (UHS) will now report Q3 2026 after the market closes on Oct. 27 and hold its earnings call on Oct. 28 at 8am ET
- Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific SymposiumANN ARBOR, Mich., October 09, 2026--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and
- AHF Champions Girls’ Health, Rights and Futures on International Day of the GirlLOS ANGELES, October 09, 2026--On International Day of the Girl, observed annually on Oct. 11, AIDS Healthcare Foundation (AHF) is calling for greater action to ensure girls everywhere have the health, education, protection, and opportunities they need to thrive and reach their full potential.
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) CongressBOSTON, October 09, 2026--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress
- SpotifyPodcasters Share Wellness Advice for World Mental Health DayOctober 10 is World Mental Health Day, but for many podcast creators, wellness is a year-round pursuit. Listeners turn to their shows for accessible self-care tools, alongside inspiring stories of resilience, growth, and community. This year, some of the most popular wellness conversations have centered around building better habits and overcoming procrastination. We’ve also seen... The post Podcasters Share Wellness Advice for World Mental Health Day appeared first on Spotify.
- Evidently Expands Clinical Data Intelligence from Patient to PopulationPALO ALTO, Calif., October 09, 2026--Evidently expands Clinical Data Intelligence from patient to population. New tools built on Omni start with a clinician's own patient list.
- Affinia TherapeuticsAffinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026WALTHAM, Mass., October 09, 2026--Affinia Therapeutics ("Affinia"), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that AFTX-201 preclinical and translational data and the Phase 1/2 UPBEAT™ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), will be featured at the Heart Failure So